112

This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.



Are there many PTCs?

By Charles-Edouard!

Well, another false testimony...

What test? Specify... The false testimony is often: I have a friend of a friend who has tried lightening... I've broken it down here: True and False Testimonials. One mistake is to lump all lightening together. Just as there is not THE vaccination but Vaccinations (some work, some don't), there is not THE alleviation but ALLEGATIONS. Forget Mono-IP (mediocre and obsolete) or TRULIGHT (to be avoided), it's rubbish. Fortunately ICCARRE (and also Mono-DTG) works very well, even excellently.

Let's take a patient, rather allergic, with multiple resistances, happy on Eviplera®. Happy yes, but for how long? When the slow, pernicious renal toxicity sets in, then, for real, he has no nice options left. Another patient, with the same profile, has started to lighten Eviplera, progressively, step by step, she is at 3/7... She postpones the renal toxicity as much: Who wants to travel far spares his mount! So you have to ask yourself questions BEFOREhand. With a good doctor: I published a list

Let's go back to the PTCs: are they numerous?

We saw in the previous post what PTCs (Post-Treatment Controllers) are: they treat, interrupt for good, the virus rises and then falls back to a very very low set-point, undetectable. Are they cured? No, it only lasts for a while, 3 years on average. The situation of the Elite controllers is rather enviable, therefore, that of the PTCs too. If the proportion of PTCs was 100%, we would be saved; if, on the contrary, it is 0%, then it is big-Pharma that is saved. That's why we never tell you about it.

The hospital of Antwerp has identified 4 PTC among its 124 exploitable patient cases: 3%.
In the CHAMP cohort it is estimated at 3%. We have the same estimate (3%) by 2 different methods: let's keep this 3%. From a medical point of view stricto sensu, these people no longer need treatment.

Many useless tritherapies

So, we have a lot of people on AIE (Abusive Extension of Indication), about 25% (?), for whom the START trial shows that there is no clinical benefit, and for whom the only benefit is to become non-contaminated.
We have 3% who could do without treatment after having taken a treatment (of induction, of what? we will see that...), and 0.5% of Elite controllers who will be put, and maintained unnecessarily, under treatment, ad vitam.

When these patients realize this, they grumble, which is normal. Dr Hocqueloux presented the state of play in the Viscontis cohort (see poster, summary). It was the occasion to remind that the Visconti cohort is post-hoc (i.e. made up of patients, early treated, controlling the virus) but that we do not manage to obtain the PTC in the cohorts of very early treated patients. Based on his fragmented observations, Dr. Hocqueloux concludes: you have to treat them early, very early, and for a long time (to hope for TPC). But where does he get this from? Where is the proof??? In France, we have cohorts of early-treated patients, so go ahead, guys, show us that you have more than 3% of PTCs. The lack of clinical benefit of treating early, too early, is explained by Dr Ananworanich Favorable clinical phenotype achieved in less than half of those treated for acute HIV infection (see slides, abstract).

So, in summary, there are poor young people who are bored with treatments, with the promise of a possible post-treatment control, which has never been shown again(SPARTAC trial and even PRIMO cohort). In ordinary chronic patients, we have 3% of PTCs and in early treated patients, who have not developed any embryonic immune response: 0%. Hocqueloux can rant on and on, the problem is there: there is no statistical or clinical benefit for the patient to treat too early.

How to condition to get more PTCs

We find more PTCs in chronic patients than in PRIMO: it is not the fact of treating in Primo that is favorable, so... it is something else... That's what we need to focus on. And here, the new Eclipse Equation sheds light on this: if we improve the EpiGeneDist and/or Immune Response factors, we increase the Eclipse. One AND/OR the other.

The observation of the A5068 trial is that we can hope to increase the rate of PTCs from 3 to 15% (or even more...), by introducing time interruptions, of modest duration (1 month) repeatedly. This is more interesting to develop than this poor Hocqueloux who is watching the cows go by, without making any progress.

Are you a PTC who doesn't know it?

To find out, and in the absence of a predictive tool, the only way is to stop and look long enough at what is happening. If you are in the LOTTI test range, it's all good: if you are a PTC, you have won the prize, if you are not, you have, at least, benefited from the LOTTI interruption (very favorable procedure). If you are in the SMART bracket, let others do it, there are better things to do: ICCARRE

Or you have a clinician who is able to do a viral expansion test in blood bags: method proposed by Van Gulck (Antwerp). If the virus has difficulties to grow in the blood bag, while it only needs a few days in vitro(in vivo it takes a few weeks...), then maybe...

The real question is: are there methods to either increase the Eclipse or to increase the number of PTCs. The Shock-and-Kill will have disappointed: 3 methods are still in the running: vacation cycles (Ragon), DTG cycles (Wainberg), Short Cycles (Leibowitch)

PTCs, Eclipse, ICCARRE and DTG

Increasing the Eclipse is not the same as increasing the number of PTCS. These are 2 different objectives, and in my personal opinion, the search for a benefit for the patient makes it more important to use ICCARRE (1/7, Leibowitch) than Ragon (PTC, Bruce Walker). This is still interesting: because one can consider combining the methods: a TRI-protocol.

We will soon see the avenues open to us...

The universal French genius

Here is a rare intervention(youtube) of Pr Schinazi. Shina-Quoi? Yes, this is the occasion to remind you that he is the inventor of 3TC, F-3TC (which almost everyone uses) and ... Sofosbuvir (which cures you of HCV in a jiffy). His Wikipedia entry. Millions of lives saved, that deserves a tribute. Especially since his speech is rich. He reminds us: 'doing nothing has consequences'.

And to remind our brilliant ANRS, SFLS, CNS, and so on that there is no French molecule... Zero, Nada... That should make you a little more humble. No?

Link

Feel free to comment, like, share and use

97% of patients overmedicated, 22 million without treatment... Let's stop this scandal!

111

This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.



By Charles-Edouard!

From a user of Kivexa/ Viramune (NVP/ABC/3TC):

Viramune is among Leibowitch's favorites. A priori we can do 4/7, since Leibo has published it in ICCARRE and the APHP has even taken out a patent. On this basis, we can go up to 2/7 or even 1/7. It would be a shame to change it. The 1/7 has been published very officiallyby Pr. Ch. Peronne, head of the infectious diseases department (the highest 'rank') and Vice-President of the Technical Committee on Vaccinations. More Kosher than that you can't do... But, well... If nobody talks about it, the patient, kept in ignorance, misses it. Too bad...

What is a PTC (Post-Treatment-Controller)?

Everyone knows the Visconti: those patients who were treated early, too much (too much?) and who, after an average of 7 years, stopped the treatment and found that the virus did not return. Asier Saez-Cirion (Pasteur Institute) published an article that made a lot of noise.

We are talking about control over very long periods, not just 3-4-5 months as is often found in Eclipse measurements. The Toronto patient (3-4 months of control) or those of Boston (9 months) are not part of this.

In France, we found these controllers in people treated early. It was concluded a bit quickly(as soon as you see the name Rouzioux, you know there is a wolf) that only early-treated patients can claim this status. We shall see below that this is not the case... Let's just remember that a PTC is a patient who controls her virus, in the long term, following a treatment and its interruption.

Are PTCs unknowing Elite Controllers?

With the AIE (Abusive Extension of Indication), patients who could hope to control their condition are put under indiscriminate, interminable treatment, without consideration of the health environment or the clinical picture. If the treatment is withdrawn, and it was useless, it will show... There, the patient is going to give the doctor(s) a hard time, that's for sure!

That's about 0.5% of the treated population. Rare, but good...

We know a little about the characteristics of these Elite controllers (who are doing very well, without treatment, thank you for them, leave them alone, you thugs!). Asier Saez-Cirion is studying these Viscontis and believes that they are not crypto-controllers-d-Elite, they don't have the profile. So don't confuse: CEs and PTCs should be counted separately...

PTCs: who are they?

The mistake would be to believe that there are ONLY the Viscontis. In fact, there are (many?) others! But to find them, you have to interrupt the treatment, and look for a long time, because the control is not instantaneous: the viral load increases at the interruption and then goes down to a new very low set-point, even < 50. Jon Barnett, author of a 'disappeared' blog, had controlled (well...) after several months (so he didn't understand anything anymore...)

PTCs are not a priori controllers, but rather following their treatment AND its interruption.

So how do you find them? Well, by chance or by looking for them!

Randomized trials of 'therapeutic vaccination'. Volunteers are 'vaccinated', either with a vaccine or a ... placebo... And we ask everyone to stop the treatment, and we look on the long term, to see if the vaccine helps to regain control. There, Oh surprise, we find 'durable controllers'!!! Bingo for the vaccine ??? Well no... They were found in the placebo group... The 'vaccine', in fact, does not work at all!

We will read: The CHAMP Cohort: Post Treatment Controllers Identified from 9 Clinical Studies: it's the topic of the moment!

Another rarity: Antwerp clinicians have found patients who have been lost to time. In Paris, you don't come to the hospital anymore, you're safe, no one comes after you... These patients are renegadesIf they do not take the treatment, they stop it on their own, do not get worse, and probably do not even know that they are in control without treatment (essential before). We see that the CV is zero. And they have a hospital record to shed light on their previous clinical picture! This is not a Belgian joke... A Belgian joke gets around, but this is total radio silence. They talk about the 'Boston patients', who in fact won't control anything, and they hide the Antwerp patients under the pharma-media carpet. Ellen Van Gulck has published: Control of viral replication after HAART discontinuationand a full description here.

PTC: How many are there? Are you? TPC and ICCARRE? TPC and DTG?

Ooh... la la ... That's all for today. Obviously the subject is fascinating. There are many things to look at under a new eye, and it will be for another time ...

Judiciarization

- Levothyrox: 42 patients sue the Merck laboratory.

- Shortage of essential drugs: the Senate and the Academy of Pharmacy sound the alarm. Considering my stock, this is not likely to happen to me... Patients on Videx (BMS) are in trouble, nobody talks about it!

In the news

- Towards a universal hepatitis C testing in France. Well... Yes... There is no point in burying our heads in the sand, especially since the more we treat, the richer Gilead gets. That alone is a good reason; in fact THE real reason?

- Test DODO : 1/2 strategy with Atripla® and also good news from the A-TRI-WEEK trial (also a 1/2...) : because we tell you!
Maintenance at 3 days per week with a single EFV / F-3TC / TDF tablet is effective and decreases subclinical toxicity. That, Gallant, he never talks about it... never... The others ... either...

- Even Alexandra Calmy goes Mono-DTG! Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study.

The French genius

Splendid, touching, energetic and still subtle. I love to succumb to the carnal power of the interpreter the interpretation! (youtube) Ah, French music!

Note: The prototype of the 'Choke-and-Mute' presentation (Pasteur on 17/05/18) is available, and soon on youtube

Of course, we will watch the France-Croatia game.

Do not hesitate to commentand share and use

good weekend, good stuffing and not too many drugs ... Right?

110

This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.



Symfi-Lo... Finally!

By Charles-Edouard!

Another litany of abuse... ICCARRE quickly!
The mithridatization, that is to say the progressive habituation to poisons, inhibitoids or inhibitors, does not remove the toxicity. It is less perceived, that's all!

Symfi-Lo = TLE-400

Symfi-Lo is the first drug to market the TLE-400(Tenofovir-Lamivudine-Efavirenz 400 mg) mitigation strategy. We discussed it in our post WHO proves us right! Well... The progress of this case will have been extremely slow, and the practical implementation is coming on the market: it is not too early! Something must have tipped off some people, and the Kirby Institute has obtained funding($11 million, if memory serves) from the Bill and Melinda GATES Foundation to launch the ENCORE-1 trial.

This involves reducing the dose of Efavirenz from 600 mg to 400 mg

Mylan launches Symfi-lo in the US.

TLE-400 unknown to the public

A few months ago, and this remains true today, a Google search on 'TLE-400' and HIV gave very few results. Actually only 2: a corporate and financial press release from Mylan (copied and pasted on financial websites) and... Charles-Edouard! Well... Now, there is a little more...

Obviously, this does not help the variety dealers... Let's also remember that it is not yet available in our country while the ENCORE-1 trial was published more than 5 years ago! And meanwhile, services are being closed to save money... Pffff...

Amazing recommendation and prioritization

When we allow, in a so-called recommendation document, a strategy that is obviously better, we are recommending it, without daring to say so.

Here is what Dr. Apollo in Harare, Zimbabwe, has to say about it:
Making the same drug with a little less of the same active ingredient is not an insurmountable industrial challenge! Well... We are not shocked that teenagers from the Third World are given priority... What shocks us is that at the usual rate, the French patient, who pays 600 Euros/month, will receive the cheaper and better tolerated formula... last! Isn't that a bit of an ass? You won't get it before 2-3 years, at best, while Mylan already claims 1 million users! We'll sell out... And who will be eating EFV 600 mg for months and months? It's you...

Morlat, Calmy: same error of judgment

And what does Morlat say about it ? He recommends it:

We have fun with it... First, he explains the 'constraint' of having to take 3 pills. As long as Symfi-Lo has not arrived in France, you're going to have a hard time! Secondly, why restrict yourself to patients who complain? When an overdose is useless, it is useless, even if it is tolerated. Useless is good French and it means what it says. Alexandra Calmy makes the same mistake, by doubling this restriction to patients who complain about a restrictive dosage condition. Well NO... Reducing the dose of VFE is clearly not a dosage restriction! Do you think they do dosing in Zimbabwe??? Prof. Calmy was wrong, and Symfi-Lo proves it, once again

Is 400 mg still too much?

Where is the trial at 200 mg, 300 mg or even 100 mg?

Who remembers that in the DMP 266-005 trial, 200 mg did BETTER than 400 mg or 600 mg? Who decided on 600? It was the manufacturer (DuPont Merck)... And no one, no one, has gone back to the drawing board with this univocal decision of the manufacturer. Why 400 and not 500? Because the 200 mg capsule packaging exists, so it's convenient to do a trial.

In fact, we had already reported the words of Pr Kiat RuxRungtham(youtube) who routinely does 300 mg. Well, it's time to ask the question of 200 mg in attack. As far as maintenance is concerned, we are in the midst of a frenzy: the 'threshold' doses are complete nonsense... We'll come back to this...

Dr. Joel Gallant: the moral and ethical fault

Dr. Joel Gallant, a drug promotion frontrunner and principal investigator for Gilead-sponsored trials, published an angry and threatening article condemning the ethical 'misconduct' of those benevolent physicians who bring Mono-DTG into their practice. It was ill-timed, remote-controlled, and in poor taste.

He was also seen ironizing about those patients who would prefer, conditionally, to preserve their psychedelic dreams and remain on Efavirenz. Ironically, to make fun of pharmaco-induced psychic suffering, which still causes thousands of suicides and depressions today, is abject and allows us to measure the immorality of the character.

To promote the latest novelty of Gilead, his sponsor, nothing stops him.

One would have thought that in his time, when he was practicing university medicine, he could have worked to reduce the deleterious effects of over-medication. This was not the case. In the DMP 266-005 trial, 200 mg did BETTER than 400 mg or 600 mg. The manufacturer, surrounded by experts(which ones?), had simply neglected this phase II trial. These trials are mandatory, they do it... Are they obliged to take them into account? Well no... You have to do an optimal dose finding trial and you are free to choose the maximum dose. And the deleterious effects? We don't care about that. Dosage is the doctors' problem. DMP 266-005 is to be thrown up.

And guess who was the principal investigator of DMP 266-005? Guess... Dr. Joel Gallant himself! Brrr, that's chilling... I hope that one day these people will be brought to trial...

In the news

- Luc Montagnier and Henri Joyeux launch a petition for precaution in medicine and health

- A study confirms the extent of the damage caused by Depakine. Depakine? That's what Siliciano is considering for his shock-and-kill... Brrr!

Feel free to comment, like, share and use

good weekend, good stuffing and not too many meds ... Huh?

97% of patients overmedicated, 22 million without treatment ... Let's stop this scandal!

109

This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.



ICCARRE and the New Paradigm

By Charles-Edouard!

Jacques Leibowitch comments on our previous post:

The prevailing dogma is that ICCARRE is impossible. Some claim that we cheated (ANRS-4D = scathing denial). They dare to add that it is only for a few: Quatuor will sink them. Other idolaters say (e.g. Prof. Reynes): 'I hope it won't go any further...' It's laughable: for sure, it will go further... It is the virus that decides... not a mandarin...

Paradigm shift: demonstration at Pasteur

The trailer of the presentation at PASTEUR is on youtube, go there!
Leibowitch starts by presenting the classical picture in 2 steps:

1. Attack-Induction-Reduction:
Attack ARV treatment should in all cases:
- CONTINUOUSLY reduce CV < 50 cp
- Monitor < 50 copies/ml continuously
- Effectively stop any HIV-dependent progression to AIDS diseases
- Reduce the risk of intimate HIV transmission to almost zero
All this, today, in less than 6 months...

ICCARRE and its DISCONTINUTES can then be summoned...: we start the ICCARRian descent(typically 1 year after initiation of treatment)

2. Maintenance Treatment, following effective induction treatment, Cellular Activation and Peri-HIV Inflammation are in Leakage, the Lymphoid Environment is cooled down and HIV is reduced to a very small size in a biotope that is naturally not conducive to replication.

Pharmacokinetics in Failure: Thinking Outside the Box

It has been known for a long time that treatment cannot be stopped without seeing the CV rise. Viscontis could be an exception, the Pasteurians (Dr. Asier Saez-Cirion) have proposed a hypothesis. So they know that pharmacokinetics are insufficient to explain that repeated interruptions of 1 week can be done safely. Demonstrated by FAUCY, the boss of the American NIH. In a way, already announced by B. Autran, an eminent French immunologist.

Pharmacokinetics does not satisfy us, and, what is more, fundamental 'values' are false: Morlat continues to publish values that in Saint Antoine were said to be false (e.g. Nevirapine): Not only the theory is wrong, but also the values!

Parisian virology is wrong: we really need to change our paradigm!

The eternal restart as a new paradigm

Everyone agrees that there is a gap between infection and seroconversion. Typically 2 to 3 weeks. No one disputes that... Nobody... The post-treatment eclipse has been demonstrated many times.

So it's surprising that the virologists are still predicting an immediate rise in CV if you stop. Well... We are not surprised anymore, actually... Denying the eclipse is as stupid as the moon!

J. Leibowitch's proposal is to say that, post effective treatment and post interruption, HIV unwinds its initial film: it is the eternal non-return, the deficiency, of the primo, repeated as a bonus!

The reader will have noted that the unchanged repetition of the deficiency implies that the eclipse cannot be manipulated (it is a cosmic fact) and that the reservoir has nothing to do with it. The Choke-and-Mute is slightly different, it considers manipulating the eclipse and extending it. Here, Charles-Edouard and Leibowitch differ slightly. No matter... The Eclipse is here: let's take advantage of it!

Post-ARV eclipses as a repeat of two-rate HIV dynamics in vivo:

A- following a recent mucosal infection: primary inoculation
or
B- interruption of synergistic ARVs: chronic infection

It takes time for HIV to complete its reproductive cycle: slow local linear growth, as in difficulty to surface (primary infection) or resurface (post ARVs). Active forms of HIV remain sub-detectable for a while until... the delayed systemic exponential explosion...

Then, Jacques Leibowitch presented the trials and examples: ICCARRE is a proven, robust way. We will see this next time...

The French genius

I'm putting back the impressive pictures of the Bomsel team (also present at the seminar... ): a little to underline their technical prowess and also ours to have succeeded in putting it online...

That plus the availability on youtube of the presentation of Leibowitch... On the technical level, we are progressing!

Judiciarization

Patients file suit against Gilead. Below is a commentary from the Los Angeles Times


Here? No one told you about that... In any case, the enormous profits made are undoubtedly a breeding ground for dubious practices. We can find traces of what Gilead spends money on: ParisSansSida, ActUp-Paris, etc. It's up to you to make up your own mind...

Do not hesitate to comment, like, share and use

good weekend, good stuffing and not too many meds ... Huh?

108

This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.



Choke and Mute: Seminar at Pasteur

By Charles-Edouard!

ICCARRE invited to the Pasteur Institute

Each presentation of Jacques Leibowitch or 4/7, in conference, arouses enthusiasm. Hugs, awards, laughter, congratulations, hearty applause, standing ovations: it never fails!

During IAS-2017, we had skilfully countered the deprogramming of ICCARE: Dr Turkova, not being shy, had slipped ICCARRE into her presentation. An invisible hand, not innocent, will have cut his entire presentation from the video session, in the editing. Well... It plays very small...

Parisian virology, mainly rotten, is nevertheless diverse, and the foundations of expensive and toxic 'medicine' has its detractors. Delelis has once again demonstrated that the classical dogma of the necessary integration into the DNA is incomplete and therefore false. Our biologists are saving the honor, even if their progress is hindered.

At Pasteur, we remember that the samples that allowed the famous discovery of the Virus (and 2 Nobel prizes) did not arrive at the Laboratory by themselves. The Pasteurian memory crosses that of ICCARRE at regular intervals. ICCARRE, dedicated, is also of interest to biologists: Dr. Olivier Schwartz, Scientific Director of the Pasteur Institute, thought it appropriate to invite J. Leibowitch to a dedicated seminar, on May 17, 2018. All the top brass of HIV biology were there: Pasteur, ENS, Inserm, Institut Cochin ... Françoise Barré-Sinoussi, always Pasteur at heart, would have been there if she had not been prevented from attending, which O. Schwartz was kind enough to ask us to excuse. No problem! Everyone, including you, will be able to view the presentations.

ICCARRE and the Paradigm shift

Pharmacokinetics could serve as a reasonable explanation for 5/7, but not at all for 1/7: we need to change the paradigm and revisit the foundations of HIV biology. With the exception of Dr. Hutter (Berlin), no doctor has ever cured a single (HIV/AIDS) patient. This should make us question ourselves a bit!

When thinking about ICCARRE, one should always keep in mind the characteristic curve of the Eclipse, otherwise one is on the wrong track. In 3 phases: down for a few days, then a sub-detectable rise, crossing the threshold of detectability to end in a spectacular ejaculation. Well... For those who have understood, it is obvious.

From ICCARRE to CHOKE-and-MUTE

Pierre Sonigo has explained many times to J. Leibowitch this dynamic chain reaction. For Sonigo or Kupieck, it is the basis of a(systemic?) biology, so fundamental and general, that they do not bother to popularize the HIV-specific version. J. Leibowitch takes it up in his book 'Pour en finir avec le Sida'. It deserves some light, which is normal for an eclipse.

The The prevailing dogma is a misconceptionand the best way to fight a misconception is to come up with a visibly better one!

It is here that yours truly, inspired by his masters, had the idea to create a didactic tool: it is the Eclipse Equation, which Leibowitch commented, rightly so:


Well done! Thus, we are going to make the New Equation of the Eclipse which exposes a way to remission, alternative to the dominant theory. Dominant... and failing, need we remind you?

Here is how, for the sake of clarity, appears on a popularizing blog an innovative concept, baptized by us theChoke-and-Mute. Indeed, ICCARRE, beyond the anecdotal relief (the 4/7, small arm), is a way to Remission! It is even an obligatory step: how could a patient who fails the 1/7 succeed the 0/365? Pass ICCARRE 1/7 and then we'll see!

Choke and Mute: Baptism at the Pasteur Institute

The paradigm shift made necessary by 1/7 goes hand in hand with a new theory of remission. The one cannot go without the other... Hence the idea of exhibiting them together in Pasteur. But then, in Pasteur, the holy of holies of world biology, you can't miss it! And it's May 17 or never, it's in a few weeks, and if the scientific direction of Pasteur is willing... Oh dear! What a challenge!

The text has been worked on, amended and revised. It remains to integrate it to Leibo's PowerPoint. Argh!!! We are caught by time! Catastrophe, it's now or never! It's for a seminar at Pasteur, and Leibo is polishing his slides, the paradigm shift. Oh! No time for Choke-and-Mute...

Disaster in the making! And we are saved: O. Schwartz accepts the principle of 2 presentations: the paradigm shift, by Leibo, and the Choke-and-Mute by... Charles-Edouard!... And that, from one day to the next!

Choke and Mute: Applause at Pasteur

Well... Despite some technical difficulties (ah... computers...) and with the help of the Pasteurians, we did great! It was really great!

We have to admit that ICCARRE, the 4/7, the Morlat recommendation, ANRS-4D, Quatuor, paradigm shift, the Eclipse, its equation, the Choke-and-Mute, and a plea for ICCARRian research, all in 1 hour, it's dense!

In a small seminar, with a learned and specialized audience, it's a good thing! Thanks to all! The hearty applause was our reward! Oh, it's clear! We have changed dimension!

The videos will be online soon

The presentations will soon be available online, in replay, once the English versions are finalized. To have them, in trial version, please leave an email address in the comments (your address will not be published).

In the news

Let's be modest: the news that counts is us! There was also:

- Immunology/Cancer: CAR-T cell breakthrough confirmed

- Finally... Finally! The first commercial 'lighter' has arrived on the market. It is the TLE-400 that we were talking about here. You will notice that nobody else is talking about it... Hi, Hi, Hi.... And Mylan introduces CimDuo ... This will do our finances a world of good, including PreP...

The French genius

Impressive images:
Live imaging of HIV-1 transfer across the virological synapse the T4 cell by Fernando Real et al. (and Morgane Bomsel, incidentally present at the seminar... )

List of videos (to be viewed separately)

- Video #1
- Video #2
- Video #3
- Video #4
- Video #5
- Video #6
- Video #7
- Video #8




Feel free to comment, like, share and use

97% of patients overmedicated, 22 million without treatment... Let's stop this scandal!

107

This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.



Isentress HD®: 10 times the dose!

By Charles-Edouard!

Isentress HD®, programmed overmedication: 10 times the dose!

With a 1/2 pill strategy, the patient reduces by 2 and is amazed! Instead of a massive dose, she takes a 1/2 dose... massive! How can we judge a reduction without knowing how much we have been cheated? The phase 2 studies should enlighten us... Not at all. Sometimes not published (ex. Efavirenz), they are systematically ignored by the manufacturer and the 'authorities': the maximum dose is always retainedI don't know of any exception. That's how we have 600 mg of EFV, 600 of ABC or 50 of DTG: the tests show that it's too much, but they sit on it! What is the use of testing!!! What is the use of 'authorities' if not as a registration chamber.

The first overmedication is theAbusive Indication Extension; we will come back to this... Another is not to differentiate between attack and maintenance. Let us mentionICCARRoPhobia, MonoPhobia or DemiPhobia.

The arrival of Isentress HD ® will reveal a spectacular increase in dose for the sole benefit of a commercial strategy. We say 10 times the dose, and we will demonstrate it.

Before the marketing of Isentress HD at 1200 mg(sic), we anticipated a drop of the dose.

Marketing will take advantage of a possible drop to twice a day to increase the dose tenfold in order to make it a once a day dose. The reformulation of Raltegravir into r-RAL shows a tripling (at least) of the dose; the too discreet pharmacokinetic tests show that the dose is at least 5 times higher. Finally, the methodological error, a la Levothirox®, shows that this factor, of at least 5, will be 10, in practice. And everyone will see nothing but fire. Your liver will pay for it!

r-RAL: proof by Dutrebis®.

RALTEGRAVIR poses a major problem of bioavailability, discussed here. In maintenance, there are 3 ways to take it: Merck style (1 tablet twice a day), German style (2, once a day), Italian style (chew 2 tablets, once a day). The tablet disintegrates badly in the stomach, its only opportunity to pass into the bloodstream, and then passes into the intestine, as if you had not taken anything! If, let's say, one out of two doses is missed, well, let's take two doses... And obviously, not at the same time. It's the same stomach... So to make sure, we will increase the dose, without taking into account that the phase 2 validated the 100 mg!

Merck's galenists will know how to improve the bioavailability: they will not say anything about it, or rather, they will not put it on the market... French. To disguise their feigned innocence, they are making a RAL/3TC combination. Lamivudine at 150 mg and RAL at... 300 mg, instead of 400: Dutrebis&reg, approved by the FDA and theEMA. No ?!! Yes!!!

Merck simply demonstrates better bioavailability. No clinical trial, too expensive: the collection of data where Dutrebis® has been distributed may be enough for the manufacturer.

Lamivudine is free, the RAL dose is reduced by 25%, so logically, its marketing would have been a loss of profit for Merck. Merck does not market it and the patients' associations, under perfusion, do not even ask for it!

r-RAL: the reformulated RALTEGRAVIR, better, not marketed...

The dose officially reduced, we will substitute 3TC with r-RAL, and make do with r-RAL alone.

The opportunity is very good: since we can reduce the dose, ensure a better bioavailability, bring everything down to a once-daily dose (QD), we hope to defend our position on the market, and, to do so, we are going to... raise the dose!

r-RAL: the pharmacokinetic proof

For a concentration, just before the new intake, equivalent to the old one, the dose must be increased: it is taken in one go. Because of the half-life (6-9 hours), it is necessary to multiply by... 4. Compared to 400 mg (BID), it would have been necessary to make 4 x 400 or 1600 mg(yuck... ), after 6 hours, there remains the equivalent of 800, and after 12 hours, the equivalent of 400 mg, that is to say what we had before... All is well!
On paper, 1600 mg is indigestible... But here, since we can do with r-RAL (300 mg) what was done with RAL (400 mg), only 1200 mg are necessary. It's yucky... But in 2 tablets of 600 mg, it becomes feasible. By taking 1200 mg you don't realize what it's like to take 1600 mg of the previous formula.

Obviously at 1200 mg of r-RAL, the patient gets a nasty boost: the peak concentration will be 4 times higher! 4 times! Four times? No, Charles-Edouard, you are forgetting that we have improved the bioavailability by 25%, so your peak will not be 4 times higher but 5!

Oh the ugly calculation! Let's go see in vivo. Merck published it: multi-dose study of Raltegravir formulations.

At first sight, the peak with r-RAL seems slightly higher than with RAL. Beware! This is a LOG scale! So the pic r-RAL is 5 times that of RAL!!!

r-RAL: 5 times the peak!? No... at least 10!

Imagine if we multiplied by 5 the Efavirenz peak... It's a guaranteed depression/suicide: an overmortality that would be visible(and yet... it would be well hidden...). Well... If we increased the peak of EFV, we would have the usual morons telling us, what they already do, that we have to take it on an empty stomach, or in the evening, or 2 hours before going to bed, or changing creamery, etc...

At 5 times the peak, we understood the topo! But 10 times?! Where does that come from? Where do you get that from? 5, I see... but not 10...

Be patient, my little rabbit... 5 is what you will have seen... Because it has been cleverly made up to you like this... You have seen, but not all of it....

To see it clearly, let's follow closely the Levothyrox® scandal(Merck, again), which the manufacturer, clinicians and 'authorities' (and the 'minister' Buzyn) will have denied en bloc. Some are clever, others gullible morons. Come on, marketing 'tricks' are tiring, we'll see next time... Go ahead and read Dr. Dupagne's truly organic equivalent #1? and #2.

In the news

- Abusive Extension of Indication: Hypothyroidism: some people treated wrongly. 3 millions take Levothyrox®: an absolute aberration... We are only surprised now ???

- Foolish practice of medicine, homeopathy: new complaints. The defense of these charlatans? Suing for non-confraternity. Let us finally decide on the merits!

- Abacavir cleared by its opponents, in spite of themselves. They advanced in camouflage, armed with smoke and mirrors, and the maneuver was foiled. For the French patient, there is no excess cardiovascular risk and the hypothesis of a mechanism of action is taking on a life of its own. We will come back to this...

The French genius

It seems that French research is making fundamental discoveries:
- Descourt / Benkirane and their reservoir marker: CD32a is a marker of a CD4 T-cell HIV reservoir
- Delelis with his 3'PPT mutation
- Estaquier, interviewed here, and his published work: Anti-caspase Q-VD-OPH prevents progression to AIDS in macaques



Feel free to comment, like, share and use

Have a good weekend, good stuffing and not too many meds ... Huh?

106

This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.



Happiness regained

By Charles-Edouard!

Here is one who has almost understood everything (well... he is discovering...):

- 3 strategies are in competition: Mono-DTG, ICCARRE or 1/2 pill

- virologists betray the trust of those who come out of the closet. Always!

The 'advisors' (stipendiaries) who invite you to trust them systematically deceive you. HIV creates an asymmetrical power relationship. Don't be naive... The doctor writes the prescription. Regain autonomy? The key is the stock! We build it, without saying anything. Mono-DTG = no stock but ICCARRE or 1/2 pill, yes! Thus, the doctor does you a favor and you can, in the long run, build up your stock and regain your freedom: ICCARRE (or 1/2 tablet), in autonomous mode, allows you to fight against ICCARRoPhobia. Long live ICCARRE-Free!

Testimony of a new found happiness

Thanks for the news! Dybyl and Faucy are the forerunners of x/7. By not pursuing it, they secured a career (director of the global fund and NIH, respectively). Having your finger on the atomic button allows you to negotiate anything you want. Just ask Kim Jun Un!

Quartet and Liberation Day

Truchis or not Truchis, ICCARRE x/7 is an inevitable Darwinian evolution...
In 4/7, the Liberation Day is Friday, July 27th! In 2/7, it was Saturday April 14th! From this day on, you are no longer the obliged slave of Gilead, ViiV, and their accomplices.

There are 240 days left before the announcement of the success of Quatuor phase I: the first 320 patients have already spent 4 months without a single announced failure! We are on the right track! With or without Truchis! I put a countdown on the top right corner.

To the obligation of treatment

Laurent Wauquiez wants to make chemical castration mandatory for ...!!! Not long ago, we chemically castrated... homosexuals(cf Turing) and this despite the Nuremberg code. It makes you think, doesn't it ?

Judiciarization

The stop of the marketing of Videx® by BMS will put a hundred patients, in therapeutic success, in a dead end! The ANSM has deceived you by announcing a generic, the Seronegs associations, acting as a patient association, are not saying a word. The only recourse: Justice. So preparations are being made for this: formal notice, lawyers, etc.

In the news

- Cigarette prices: manufacturers do not want to 'kill the goose that lays the golden eggs

- MK-8591, an NRTTI (not NNRTI...) could allow for weekly commercial catch; that is, adding the eclipse, 1/15!

- A brilliant idea has just appeared on the tickers: Juluca ® + Descovy ® in 1/7. 2 small pills taken weekly. It smells like a good plan! We'll come back to it...

- We could reformulate Efavirenz to dose at 100 mg

The French genius

I put you an exchange between Garches and a thing, the TRT-5, whose utility escapes me... French genius (?!)...
- The initial questions
- the answers provided by Garches

Find Jean Marais, so right when he says: By the way, don't you think it's strange that everyone tries to be physically beautiful, while it's possible for anyone to be morally beautiful and no one does it (on Youtube, at minute 1:40)

Another version of C. Franck's Fugue: Latry, on the organ.

Feel free to comment, like, share and use

97% of patients overmedicated, 22 million without treatment... Let's stop this scandal!